How European Supplementary Protection Certificates actually work, why their expiry dates keep moving, and what that means for your market […]
EU SPC Expiry Decoded: The Competitive Playbook Every Pharma Strategist Needs Read Post »
Executive Summary How to win 180-day exclusivity, survive the price erosion curve, and build a future-proof portfolio in a $491B
Generic Drug Launch Strategy: The Complete IP, Regulatory & Commercial Playbook Read Post »
I. The $300 Billion Opportunity Hiding in Plain Sight The most reliable, legally mandated, and fiscally massive cost-containment event in
Patent Cliff Playbook: How Payers Capture Billions from Drug LOE Events Read Post »
The 20-year patent term is the most cited number in pharmaceutical business strategy. It is also, in practice, a fiction.
Part I: The Exclusivity Architecture: What Executives Get Wrong About the 20-Year Rule The number ’20 years’ is the most
Pharma Patent Expiration Calendar: The Complete LOE Strategy Guide Read Post »
Why This Cliff Is Different Generic and biosimilar drugs saved the U.S. healthcare system an estimated $3.1 trillion over the
Patent Cliff Playbook: How Generic Firms Win $200B in Off-Patent Drug Markets Read Post »
The generic pharmaceutical industry has spent thirty years perfecting a business model that no longer works. The playbook was elegant
A deep-dive strategic guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on the regulatory, patent, and
Who this is for: IP teams at innovator and generic companies, portfolio managers running LOE models, R&D leads evaluating lifecycle
Sign in or create a free account to read this DrugPatentWatch article
